Savara (SVRA)
5.21
-0.13 (2.43%)
Upcoming Events
Latest Headlines
Savara to present IMPALA-2 trial data at ERS Congress in Barcelona
August 24, 2026 4:05 PM - StreetInsider
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
August 24, 2026 4:05 PM - BizWire
Savara Announces New Employment Inducement Grant
August 20, 2026 4:05 PM - BizWire
Form SCHEDULE 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 14, 2026 8:23 AM - SEC Filing
Form S-8 Savara Inc
August 11, 2026 5:12 PM - SEC Filing
Form 10-Q Savara Inc For: Jun 30
August 11, 2026 4:06 PM - SEC Filing
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026 4:05 PM - BizWire
Savara wins European and Australian patents for Molbreevi through 2041
July 30, 2026 8:05 AM - StreetInsider
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
July 30, 2026 8:05 AM - BizWire
Form 4 Savara Inc For: Jul 15 Filed by: Lutz Robert Matthew
July 24, 2026 6:25 PM - SEC Filing
Palvella Therapeutics adds Matt Pauls to its board of directors
June 30, 2026 7:30 AM - StreetInsider
Form 4 Savara Inc For: Jun 22 Filed by: Lowrance David L
June 22, 2026 8:18 PM - SEC Filing
Form 144 Savara Inc Filed by: Lowrance David L
June 22, 2026 3:09 PM - SEC Filing
Full Article List
